Clinical trial

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)

Name
P05528
Description
This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.
Trial arms
Trial start
2008-07-01
Estimated PCD
2008-10-01
Trial end
2008-10-01
Status
Completed
Phase
Early phase I
Treatment
Mometasone furoate nasal spray (MFNS)
MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
Arms:
Arm 1
Other names:
Nasonex Nasal Spray
Matching placebo nasal spray
Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Arms:
Arm 2
Other names:
Placebo
Size
324
Primary endpoint
The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days.
15 days of treatment
Eligibility criteria
Inclusion Criteria: * A subject must be 12 years of age or older, of either sex, and of any race. * A subject must have at least a 2-year history of SAR which exacerbates during the study season. * A subject must have a positive skin prick test response to an appropriate seasonal allergen at Visit 1. * A subject must be clinically symptomatic at the Screening and Baseline Visits. Exclusion Criteria: * A subject with a history of severe local reaction(s) or anaphylaxis to skin testing. * A subject who has had an upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14-day washout prior to the Screening Visit, or who has had a viral upper respiratory infection within 7 days prior to the Screening Visit. * A subject who has used any drug in an investigational protocol in the 30 days prior to the Screening Visit. * A subject who is participating in any other clinical study. * A subject who is part of the staff personnel directly involved with this study. * A subject who is a family member (parent, spouse, or sibling) of the investigational study staff. * A female subject who is breast-feeding, pregnant, or intends to become pregnant. * A subject previously randomized into this study. * A subject who has a family member (parent, spouse, or sibling) currently enrolled in this study.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 324, 'type': 'ACTUAL'}}
Updated at
2024-05-21

1 organization

2 products

1 indication

Organization
Organon and Co